EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer

Guo-Bin Song, Lin Xiang, Tian Peng, Ya-Nan Li, Hou-Qun Ying, Xue-Xin Cheng

International Journal of Medical Sciences · 2025

DOI: 10.7150/ijms.113736 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Medical Sciences, 2025. Verfasst von Guo-Bin Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Cl…. Hauptthemen laut MEDLINE: Neoplasms, Chromosomal Proteins, Non-Histone. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ACTL6A, a core subunit of the SWI/SNF chromatin remodeling complex, has emerged as a critical oncogenic driver across multiple malignancies. Recent studies reveal that aberrant ACTL6A overexpression promotes tumor initiation, progression, and metastasis by orchestrating chromatin remodeling, transcriptional reprogramming, and crosstalk with key signaling pathways (e.g., Hippo/YAP, Notch, and PI3K/AKT). This review systematically synthesizes evidence from in vitro, in vivo, and clinical studies spanning hepatocellular carcinoma, breast cancer, glioblastoma, and 10 other cancer types, highlighting ACTL6A's dual role as a chromatin remodeler and an independent oncogenic effector. Key mechanisms include sustaining cancer stemness, suppressing apoptosis, enhancing DNA repair, and driving metabolic reprogramming. Clinically, ACTL6A overexpression correlates with advanced tumor stage, therapy resistance, and poor prognosis, positioning it as a promising prognostic biomarker and therapeutic target. We further discuss emerging strategies to inhibit ACTL6A (e.g., siRNA, small-molecule inhibitors) and propose combinatorial approaches to overcome drug resistance. By integrating multi-omics data and preclinical models, this review not only clarifies ACTL6A's context-dependent oncogenic networks but also bridges mechanistic insights to translational challenges, offering a roadmap for future research and therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsChromosomal Proteins, Non-HistoneHumansOncogenesMolecular Targeted TherapySignal TransductionGene Expression Regulation, NeoplasticAnimalsChromatin Assembly and DisassemblyDrug Resistance, NeoplasmBiomarkers, Tumor

Stichwörter der Autor:innen

ACTL6Acancerchromatin remodelingtherapeutic targettumor progression

Substanzen

Chromosomal Proteins, Non-HistoneBiomarkers, Tumor

Autor:innen und Institutionen

  • Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical Col…

Zitieren

APA

Song, G. B., Xiang, L., Peng, T., Li, Y. N., Ying, H. Q., & Cheng, X. X. (2025). Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.113736

Vancouver

Song GB, Xiang L, Peng T, Li YN, Ying HQ, Cheng XX. Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer. International Journal of Medical Sciences. 2025. doi:10.7150/ijms.113736

BibTeX
@article{Song2025,
  author = {Song, Guo-Bin and Xiang, Lin and Peng, Tian and Li, Ya-Nan and Ying, Hou-Qun and Cheng, Xue-Xin},
  title = {Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer},
  journal = {International Journal of Medical Sciences},
  year = {2025},
  doi = {10.7150/ijms.113736}
}
Kostenlos starten →